A study evaluating the post-progression survival (PPS) in patients undergoing sorafenib for advanced hepatocellular carcinoma (HCC) based on Albumin-Bilirubin (ALBI) grade.
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 06 Jan 2017 New trial record